Fiskars hosted its CMD event yesterday. The company announced new financial targets for 2026-30 whic...
* Orviglance data accepted for presentation at high-quality congress * Cash runway into 2027 * Fair ...
Sales took a backwards step in Q1, with all regions posting a muted performance.
Today, new data from BI-1808 in cutaneous T-cell lymphoma were presented.
Hyresintäkterna steg 5,5% till 129,0 mkr drivet av indexering och högre uthyrningsgrad (95,5%).
Hyresintäkterna ökade 15% till 208 mkr drivet av förvärv, indexering och investeringar.
* Svedbergs Group acquires Czech Group UBC s.r.o. * Acquires 80% initially, remaining 20% planned in...
Envar rapporterade för Q1’26 en nettoomsättning om 25,8 MSEK (22,7), motsvarande en tillväxt om 13,6...
Endomines Q1 results were operatively well in line with our expectations, with revenue at EUR 18.
CTEK delivered a relatively strong Q1 report despite continued weak end markets, with Consumer once ...
BeammWave has resolved a directed issue of ~SEK20m to institutional investor MetaSpace Fund and a co...
Redeye comments on Transtema’s Q1 report. While the adjusted EBITA was somewhat softer than expected...
Q1 showed sales decreasing 8% y/y, leading to a miss of 8% vs SEB expectations.
Redeye provides its initial take on Moberg Pharma’s Q1 report, which saw sales slightly exceed expec...
Yesterday, QBY reported Q1'26 results that came in below our already cautious estimates.
* NOI 5% y-o-y, +3.4% vs ABGSCe, +1.3% vs cons. * Value changes of +0.
Alzecures fas 1b-studie med ACD856 på fyrtio friska frivilliga deltagare är slutförd enligt plan.
Q1 looks solid, with a 9% PFPM beat versus consensus, positive value changes (0.
Redeye updates on W5 Solutions after Q1-results which were better-than-expected.
Redeye returns with a revised outlook following GomSpace's Q1 report that demonstrated financial pro...
